A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
23
06
2020
revised:
01
09
2020
accepted:
05
10
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers. Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence of IRAEs ranging from 2% to 5%. Most of the initial data related to kidney IRAEs have focused on acute interstitial nephritis (AIN). There are minimal data on the types and relative frequencies of glomerular diseases associated with ICIs, their treatment, and outcomes. We performed a systematic review and meta-analysis of all biopsy-proven published cases/series of glomerular pathology associated with ICIs. We searched the MEDLINE, EMBASE, and Cochrane databases from inception to February 2020. We abstracted patient-level data, including demographics, cancer and ICI therapy details, and characteristics of kidney injury. After screening, 27 articles with 45 cases of biopsy-confirmed ICI-associated glomerular disease were identified. Several lesion types were observed, with the most frequent being pauci-immune glomerulonephritis (GN) and renal vasculitis (27%), podocytopathies (24%), and complement 3 GN (C3GN; 11%). Concomitant AIN was reported in 41%. Most patients had ICIs discontinued (88%), and nearly all received corticosteroid treatment (98%). Renal replacement therapy (RRT) was required in 25%. Most patients had full (31%) or partial (42%) recovery from acute kidney injury (AKI), although 19% remained dialysis-dependent, and approximately one-third died. Complete or partial remission of proteinuria was achieved in 45% and 38%, respectively. Multiple forms of ICI-associated glomerular disease have been described. Pauci-immune GN, podocytopathies, and C3GN are the most frequently reported lesions. ICI-associated glomerular disease may be associated with poor kidney and mortality outcomes. Oncologists and nephrologists must be aware of glomerular pathologies associated with ICIs and consider obtaining a kidney biopsy specimen when features atypical for AIN are present.
Identifiants
pubmed: 33426386
doi: 10.1016/j.ekir.2020.10.002
pii: S2468-0249(20)31640-5
pmc: PMC7783581
doi:
Types de publication
Journal Article
Langues
eng
Pagination
66-77Informations de copyright
© 2020 International Society of Nephrology. Published by Elsevier Inc.
Références
Clin Kidney J. 2019 Feb;12(1):81-88
pubmed: 30746132
J Immunother Cancer. 2017 Jul 18;5(1):57
pubmed: 28716106
Am J Nephrol. 2017;45(2):160-169
pubmed: 28076863
Curr Probl Cancer. 2017 Mar - Apr;41(2):100-110
pubmed: 28189263
BMC Nephrol. 2016 Nov 22;17(1):188
pubmed: 27876011
Nat Rev Nephrol. 2019 Mar;15(3):129-143
pubmed: 30692664
J Immunother Cancer. 2019 Jan 6;7(1):2
pubmed: 30612580
J Skin Cancer. 2016;2016:3874572
pubmed: 27648306
J Dermatol. 2019 Dec;46(12):1197-1201
pubmed: 31638282
J Clin Oncol. 2019 Aug 20;37(24):2162-2170
pubmed: 29906252
BMC Cancer. 2016 Aug 19;16:656
pubmed: 27543082
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Drugs. 2018 Sep;78(14):1443-1457
pubmed: 30187355
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Immunother. 2020 Jan;43(1):29-31
pubmed: 31567702
Am J Kidney Dis. 2016 Aug;68(2):287-291
pubmed: 27113507
Elife. 2018 Jan 16;7:
pubmed: 29336304
JAMA. 2018 Jun 19;319(23):2437-2439
pubmed: 29922818
BMC Nephrol. 2018 Jul 3;19(1):156
pubmed: 29970032
Eur J Cancer. 2020 Jan;125:46-48
pubmed: 31838404
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
CEN Case Rep. 2020 Feb;9(1):48-54
pubmed: 31605271
Am J Kidney Dis. 2017 Oct;70(4):581-585
pubmed: 28648302
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1692-1700
pubmed: 31672794
J Immunother. 2017 Nov/Dec;40(9):345-348
pubmed: 28961608
Clin Kidney J. 2019 Feb;12(1):78-80
pubmed: 30746131
Oncoimmunology. 2017 Jul 13;6(10):e1349587
pubmed: 29123963
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289
pubmed: 30865922
Intern Med. 2018 May 1;57(9):1259-1263
pubmed: 29279511
J Clin Oncol. 2018 Feb 1;36(4):391-398
pubmed: 29040030
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Rev Assoc Med Bras (1992). 2019 Aug 05;65(7):934-936
pubmed: 31389500
Lung Cancer. 2018 Aug;122:22-24
pubmed: 30032835
J Am Soc Nephrol. 2020 Feb;31(2):435-446
pubmed: 31896554
Nat Rev Nephrol. 2018 Sep;14(9):571-588
pubmed: 30013100
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
J Natl Compr Canc Netw. 2020 Mar;18(3):355-361
pubmed: 32135514
Kidney Int. 2016 Mar;89(3):720
pubmed: 26880464
Kidney Int. 2020 Jan;97(1):62-74
pubmed: 31685311
Clin Kidney J. 2019 Apr 19;12(4):503-511
pubmed: 31384441
Case Rep Nephrol. 2019 Jan 15;2019:3614980
pubmed: 30775040
BMJ Evid Based Med. 2018 Apr;23(2):60-63
pubmed: 29420178
J Thorac Oncol. 2017 Aug;12(8):e103-e105
pubmed: 28342816
BMC Nephrol. 2019 Oct 11;20(1):366
pubmed: 31604452
Am J Ther. 2015 May-Jun;22(3):e84-7
pubmed: 24067875
Intern Med. 2020 Apr 1;59(7):977-981
pubmed: 31813918
Kidney Int. 2019 Jul;96(1):252
pubmed: 31229042
Nephrol Dial Transplant. 2017 Jun 1;32(6):936-942
pubmed: 28025384
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Eur J Cancer. 2020 Feb;126:74-77
pubmed: 31923730
Br J Cancer. 2016 Dec 6;115(12):1457-1461
pubmed: 27832664
N Engl J Med. 2018 Mar 22;378(12):1163
pubmed: 29565518
Kidney Int. 2016 Sep;90(3):638-47
pubmed: 27282937
Semin Oncol. 2010 Oct;37(5):430-9
pubmed: 21074057
J Clin Invest. 2013 Apr;123(4):1773-83
pubmed: 23549081
Kidney Int Rep. 2018 Oct 29;4(2):355-359
pubmed: 30775635
Kidney Int. 2016 Sep;90(3):474-6
pubmed: 27521108
Am J Kidney Dis. 2019 Dec;74(6):853-856
pubmed: 31204194
JAMA. 2019 Mar 26;321(12):1218-1219
pubmed: 30912827
N Engl J Med. 2009 Jul 9;361(2):211-2
pubmed: 19587352